MedTrace Logo

Decitabine for Chemotherapy Unfit Korean AML Patients in Real Practice

NCT02698124 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 136

Last updated 2016-03-07

No results posted yet for this study

Summary

Prospective multicenter, open-lab el, observational, single arm study of decitabine. Subjects will be elderly patients with newly diagnosed, treatment-naïve AML who are unfit to receive and not candidate for intensive induction chemotherapy (iIC)

Conditions

Interventions

DRUG

Decitabine

Sponsors & Collaborators

  • The Korean Society of Hematology, AML/MDS Working Party

    collaborator UNKNOWN

  • Ulsan University Hospital

    lead OTHER

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-03-31
Primary Completion
2019-08-31
Completion
2022-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02698124 on ClinicalTrials.gov